Buy “Clinical Psychopharmacology” book and
receive a 10% discount on this course, equivalent to getting the book for free for the CME course or at half price or greater discount for non-CME courses.
Simply email the receipt from your book purchase to info@psychiatryletter.com to receive the discount.
This material is all-new and different from the Advanced Psychopharmacology course. We recommend that you take the Advanced Psychopharmacology course before taking the update course, as this new material builds on the basic concepts presented in the earlier course.
Receive 8 hours of CME or CEU credits for 8 one-hour lectures. Physicians, Registered Nurses, Nurse Practitioners, and Physician Assistants can accept AMA PRA Category 1 Credits. Psychologists can receive credits in most states also (check with your state board).
$399.00
All recordings will remain available to you for up to 3 years. The fee is for the entire course, and you will receive an email in response with the course link within 5 business days of booking. All recordings will be made available upon booking for a total of 8 sessions.
Accreditation and Designation Statements and Disclosure Report
Psychopharmacology Update Fall 2022
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and The Psychiatry Letter. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.
PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Enduring activity date: November 15, 2022 – November 15, 2023
Financial Disclosures
The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:
“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”
Full Legal Name Commercial Interest Role Level of participation in the activity
Nassir Ghaemi Novartis Employee until 2021 Speaker/Planner
These financial relationship(s) with ineligible companies have been mitigated by PeerPoint Medical Education Institute and The Psychiatry Letter.
All other presenters, planners, editors, or staff report no relationships to disclose:
“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”
Listen to Dr. Nassir Ghaemi and PL faculty present 8 recorded classes in 1 hour blocs. Watch at your own convenience.
Recorded sessions include:
Video 1: New antipsychotics: Psychopharmacology update 2023 - Dr. Nassir Ghaemi
Video 2: New dopamine blocker/modulators...new clinical experiences - Dr. Paul Vohringer
Video 3: Monoamine agonists (Antidepressants): Update on recent studies and new medications - Dr. Nassir Ghaemi
Video 4: Glutamate NMDA Antagonists: Conceptual Development and Current Clinical Uses - Dr. Paul Vohringer
Video 5: Psychiatric Drug development: Why can't we do better? - Dr. Nassir Ghaemi
Video 6: Digital psychiatry: A brave new world - Dr. Nassir Ghaemi
Video 7: Mood temperaments: Diagnosis and recent research on treatment - Dr. Paul Vohringer
Video 8: New studies on current medications - Dr. Nassir Ghaemi
Q: I was wondering if you've used genetic testing to help choose an antidepressant. I have one patient who is requesting it but hasn't actually "failed" any antidepressant trials. She doesn't like the idea of waiting several weeks just to find out something may not...
Q: I have a question about Lithium Orotate 10 mg or other low dose. I have a few patients who cannot accept their manic depressive diagnosis but they would accept Lithium Orotate OTC low dose. I suggested it to one after doing the usual labs and EKG. She said it is...
An underappreciated medicationUse the slow release formBest clinical usesFormulations, mechanisms, dosing, and pharmacokineticsDrug interactionsSide effectsMedical risks An underappreciated medication Carbamazepine is an underappreciated drug. Its lack of weight...
Reviews